Management ChangeJun 9, 2026, 04:22 PM
Renatus Tactical Acquisition Director Resigns, Causing Nasdaq Non-Compliance
AI Summary
Matan Fattal resigned as a director and from all committees of Renatus Tactical Acquisition Corp I, effective June 5, 2026. This resignation was not due to any dispute. As a result, the company is temporarily non-compliant with Nasdaq Listing Rules 5605(c)(2)(A) and 5605(b), which require a minimum of three independent audit committee members and a majority of independent directors on the board, respectively. The company currently has two independent and two non-independent directors, with one vacant seat. Renatus Tactical Acquisition Corp I intends to use Nasdaq's cure periods and is actively seeking a new independent director to regain compliance.
Key Highlights
- Matan Fattal resigned as a director of Renatus Tactical Acquisition Corp I, effective June 5, 2026.
- He also resigned from the Audit, Compensation, and Nominating and Corporate Governance Committees.
- Resignation was not due to any dispute or disagreement with the company or its Board.
- Company is non-compliant with Nasdaq Rule 5605(c)(2)(A) regarding audit committee composition.
- Company is non-compliant with Nasdaq Rule 5605(b) regarding a majority of independent directors on the Board.
- The Board currently has two independent, two non-independent directors, and one vacant seat.
- Company intends to rely on Nasdaq cure periods to regain compliance.
- Company is actively searching for a new independent director for the Board and Audit Committee.
Price Impact
More from RTAC